NASDAQ : IMMX
Immix Biopharma, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 7.98 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 661.57M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company’ lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Details
| Name | Immix Biopharma, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 21 |
| Founded | 2014 |
| Ipo Date | 2021-12-16 |
| Ceo | Ilya Rachman |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 5.00 |
| Isin | US45258H1068 |
| Cusip | 45258H106 |
| Cik | 1873835 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Ilya Rachman M.B.A., M.D., Ph.D. | Co-Founder, Chief Executive Officer, Chief Scientific Officer and Chairman |
| Gabriel Morris B.A. | President, Chief Financial Officer and Director |
| Dr. Vladimir P. Torchilin D.Sc., MSE, Ph.D. | Scientific Co-Founder |
| Dr. Graham Ross FFPM, M.D. | Chief Medical Officer and Head of Clinical Development |
| Dr. David Marks MBBS, Ph.D. | Chief Medical Officer of Cell Therapy |
| Mel Davis-Pickett | Head of CMC Technical Development |
| Michael A. Grabow | Chief Commercial Officer |
Contact
| Address | 11400 West Olympic Boulevard, Suite 200, Los Angeles, California 90064, United States |
| Phone | 310 651 8041 |
| Website | https://www.immixbio.com |